A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients

被引:72
|
作者
Borges, J. L. C. [1 ]
Bilezikian, J. P. [2 ]
Jones-Leone, A. R. [3 ]
Acusta, A. P. [3 ]
Ambery, P. D. [4 ]
Nino, A. J. [3 ]
Grosse, M. [4 ]
Fitzpatrick, L. A. [5 ]
Cobitz, A. R. [3 ]
机构
[1] Univ Catolica Brasilia, Dept Endocrinol, Brasilia, DF, Brazil
[2] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA
[3] GlaxoSmithKline, Med Dev Ctr, King Of Prussia, PA USA
[4] GlaxoSmithKline, Med Dev Ctr, Stockley Pk, Middx, England
[5] GlaxoSmithKline, Med Dev Ctr, Upper Merion, PA USA
来源
DIABETES OBESITY & METABOLISM | 2011年 / 13卷 / 11期
关键词
Avandamet; bone mineral density; drug-naive; FPG; Hb1Ac; metformin; type; 2; diabetes; RECEPTOR-GAMMA AGONIST; INSULIN-RESISTANCE; ADIPONECTIN; MONOTHERAPY; DECREASES; FRACTURES; THERAPY; MARKERS;
D O I
10.1111/j.1463-1326.2011.01461.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: The purpose of this study was to evaluate if superior glycaemic control could be achieved with Avandamet (R) (rosiglitazone/metformin/AVM) compared with metformin (MET) monotherapy, and if glycaemic effects attained with AVM are durable over 18 months of treatment. Bone mineral density (BMD) and bone biomarkers were evaluated in a subgroup of patients. Methods: This was a phase IV, randomized, double-blind, multi-centre study in 688, drug naive, male and female patients who had an established clinical diagnosis of type 2 diabetes mellitus (T2DM). Patients were randomized in a 1 : 1 ratio either to AVM or MET. Results: As initial therapy in patients with T2DM, AVM was superior to MET in achieving statistically significant reductions in glycated haemoglobin (HbA1c) (p < 0.0001) and fasting plasma glucose (FPG) (p < 0.001), with more patients reaching recommended HbA1c and FPG targets for intensive glycaemic control. The glycaemic effects attained with AVM compared to MET monotherapy were durable over 18 months of treatment. In the bone substudy, AVM was associated with a significantly lower BMD in comparison with MET at week 80 in the lumbar spine and total hip (p < 0.0012 and p = 0.0005, respectively). Between-treatment differences were not statistically significant for distal one-third of radius BMD, femoral neck BMD or total BMD. Conclusion: Superior glycaemic control was achieved with AVM compared with MET monotherapy. The superior glycaemic effects were shown to be durable over 18 months of treatment. AVM was associated with a significantly reduced BMD in comparison with MET at week 80 in the lumbar spine and total hip.
引用
收藏
页码:1036 / 1046
页数:11
相关论文
共 50 条
  • [41] Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
    Ji, Linong
    Du, Ying
    Xu, Min
    Zhou, Xiangjun
    Mo, Zhaohui
    Ma, Jianhua
    Li, Jiarui
    Li, Yufeng
    Lin, Jingna
    Wang, Yanjun
    Yang, Jing
    Song, Weihong
    Jin, Hui
    Pang, Shuguang
    Liu, Hui
    Li, Ping
    Liu, Jie
    Yao, Minxiu
    Li, Wenhui
    Jiang, Xiaohong
    Shen, Feixia
    Geng, Houfa
    Zhou, Haifeng
    Ran, Jianmin
    Lei, Minxiang
    Du, Yinghong
    Ye, Shandong
    Guan, Qingbo
    Lv, Wenshan
    Tan, Huiwen
    Chen, Tao
    Yang, Jinkui
    Qin, Guijun
    Li, Shiyun
    Chen, Lei
    DIABETOLOGIA, 2021, 64 (05) : 1066 - 1078
  • [42] Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
    Linong Ji
    Ying Du
    Min Xu
    Xiangjun Zhou
    Zhaohui Mo
    Jianhua Ma
    Jiarui Li
    Yufeng Li
    Jingna Lin
    Yanjun Wang
    Jing Yang
    Weihong Song
    Hui Jin
    Shuguang Pang
    Hui Liu
    Ping Li
    Jie Liu
    Minxiu Yao
    Wenhui Li
    Xiaohong Jiang
    Feixia Shen
    Houfa Geng
    Haifeng Zhou
    Jianmin Ran
    Minxiang Lei
    Yinghong Du
    Shandong Ye
    Qingbo Guan
    Wenshan Lv
    Huiwen Tan
    Tao Chen
    Jinkui Yang
    Guijun Qin
    Shiyun Li
    Lei Chen
    Diabetologia, 2021, 64 : 1066 - 1078
  • [43] Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)
    Pan, Chang Yu
    Han, Ping
    Liu, Xiaoming
    Yan, Shengli
    Feng, Ping
    Zhou, Zhiguang
    Lv, Xiaofeng
    Tian, Hui
    Kui, Yang Jin
    Su, Benli
    Shang, Shuhua
    Niemoeller, Elisabeth
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 (08) : 726 - 735
  • [44] A multicentre, randomized, double-blind, parallel, active- and placebo-controlled Phase 3 clinical study of the glucokinase activator PB-201 in treatment-naive patients with type 2 diabetes mellitus: A study protocol
    Du, Ying
    Gao, Leili
    Xiao, Xinhua
    Hou, Xin
    Ji, Linong
    DIABETES OBESITY & METABOLISM, 2023, 25 (03): : 649 - 655
  • [45] Effects of long-term, therapy (2-year) with muraglitazar, a novel dual PPAR α/γ agonist, on diabetic dyslipidemia in patients with type 2 diabetes:: A double-blind, randomized, parallel-group study
    Frederich, R
    Viraswami-Appanna, K
    Rubin, CJ
    DIABETES, 2005, 54 : A236 - A236
  • [46] Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC)
    Gao, Bin
    Gao, Weiguo
    Wan, Hailong
    Xu, Fengmei
    Zhou, Rong
    Zhang, Xia
    Ji, Qiuhe
    DIABETES OBESITY & METABOLISM, 2022, 24 (06): : 991 - 999
  • [47] Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial
    Terauchi, Yasuo
    Tamura, Masahiro
    Senda, Masayuki
    Gunji, Ryoji
    Kaku, Kohei
    DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1397 - 1407
  • [48] Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
    Linong Ji
    Ying Du
    Min Xu
    Xiangjun Zhou
    Zhaohui Mo
    Jianhua Ma
    Jiarui Li
    Yufeng Li
    Jingna Lin
    Yanjun Wang
    Jing Yang
    Weihong Song
    Hui Jin
    Shuguang Pang
    Hui Liu
    Ping Li
    Jie Liu
    Minxiu Yao
    Wenhui Li
    Xiaohong Jiang
    Feixia Shen
    Houfa Geng
    Haifeng Zhou
    Jianmin Ran
    Minxiang Lei
    Yinghong Du
    Shandong Ye
    Qingbo Guan
    Wenshan Lv
    Huiwen Tan
    Tao Chen
    Jinkui Yang
    Guijun Qin
    Shiyun Li
    Lei Chen
    Diabetologia, 2021, 64 : 1900 - 1901
  • [49] A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin
    Jain, Aditi
    Vispute, Abhay
    Dange, Amol
    Naskar, Arindam
    Mondal, Asish
    Vivekanand, B.
    Sharma, Balram
    Varade, Deepak
    Shukla, Dhaiwat
    Bhatia, Girish
    Chaudhari, Harshal
    Ram Babu, K.
    Gavali, Onkar
    Sorate, Sanket
    Bhanushali, Shaishav
    Kothari, Vaibhav
    Khandelwal, Vipul
    Sharma, Akhilesh
    Pawar, Roshan
    Mayabhate, Mayur
    Shahavi, Vinayaka
    Rajput, Aashishsingh
    Jaiswal, Mukesh
    DIABETES THERAPY, 2024, 15 (01) : 61 - 76
  • [50] A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin
    Aditi Jain
    Abhay Vispute
    Amol Dange
    Arindam Naskar
    Asish Mondal
    B. Vivekanand
    Balram Sharma
    Deepak Varade
    Dhaiwat Shukla
    Girish Bhatia
    Harshal Chaudhari
    K. Ram Babu
    Onkar Gavali
    Sanket Sorate
    Shaishav Bhanushali
    Vaibhav Kothari
    Vipul Khandelwal
    Akhilesh Sharma
    Roshan Pawar
    Mayur Mayabhate
    Vinayaka Shahavi
    Aashishsingh Rajput
    Mukesh Jaiswal
    Diabetes Therapy, 2024, 15 : 215 - 227